1. Home
  2. SNGX vs LDWY Comparison

SNGX vs LDWY Comparison

Compare SNGX & LDWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • LDWY
  • Stock Information
  • Founded
  • SNGX 1987
  • LDWY 1990
  • Country
  • SNGX United States
  • LDWY United States
  • Employees
  • SNGX N/A
  • LDWY N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • LDWY Advertising
  • Sector
  • SNGX Health Care
  • LDWY Consumer Discretionary
  • Exchange
  • SNGX Nasdaq
  • LDWY Nasdaq
  • Market Cap
  • SNGX 10.1M
  • LDWY 9.2M
  • IPO Year
  • SNGX 1987
  • LDWY 1991
  • Fundamental
  • Price
  • SNGX $2.92
  • LDWY $4.91
  • Analyst Decision
  • SNGX Strong Buy
  • LDWY
  • Analyst Count
  • SNGX 1
  • LDWY 0
  • Target Price
  • SNGX $6.00
  • LDWY N/A
  • AVG Volume (30 Days)
  • SNGX 10.0M
  • LDWY 5.1K
  • Earning Date
  • SNGX 11-07-2025
  • LDWY 08-28-2025
  • Dividend Yield
  • SNGX N/A
  • LDWY N/A
  • EPS Growth
  • SNGX N/A
  • LDWY N/A
  • EPS
  • SNGX N/A
  • LDWY 1.66
  • Revenue
  • SNGX N/A
  • LDWY $71,244,000.00
  • Revenue This Year
  • SNGX N/A
  • LDWY N/A
  • Revenue Next Year
  • SNGX N/A
  • LDWY N/A
  • P/E Ratio
  • SNGX N/A
  • LDWY $3.03
  • Revenue Growth
  • SNGX N/A
  • LDWY 187.12
  • 52 Week Low
  • SNGX $1.09
  • LDWY $3.02
  • 52 Week High
  • SNGX $6.23
  • LDWY $6.19
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 51.64
  • LDWY 38.28
  • Support Level
  • SNGX $2.58
  • LDWY $5.22
  • Resistance Level
  • SNGX $3.11
  • LDWY $5.35
  • Average True Range (ATR)
  • SNGX 0.22
  • LDWY 0.33
  • MACD
  • SNGX -0.09
  • LDWY -0.07
  • Stochastic Oscillator
  • SNGX 43.59
  • LDWY 17.42

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About LDWY Lendway Inc. (DE)

Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.

Share on Social Networks: